ABUS vs LULU · P/E 5.4, rev $180.1M vs P/E 17, rev $11.10B
Arbutus Biopharma Corp (ABUS) versus Lululemon Athletica Inc. (LULU) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Lululemon Athletica Inc. (LULU) is a apparel retail company listed on US. It is led by Calvin McDonald.
Latest reported ABUS revenue for 2026-06-30 was $180.1M. Net income was $164.6M. Revenue was up 0.6% from 2026-03-31 to 2026-06-30. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported LULU revenue for 2026-02-01 was $11.10B. Net income was $1.58B. Revenue was up 4.9% from 2025-02-02 to 2026-02-01. LULU currently screens at market cap $29.68B and trailing P/E 16.8.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. LULU currently screens at market cap $29.68B and trailing P/E 16.8.
Not investment advice. Open the ABUS and LULU stock pages for the full models.
Not investment advice.